Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661
Debt
Debt-to-Equity RatioN/A
Current Ratio11.52
Quick Ratio11.52
Price-To-Earnings
Trailing P/E Ratio-3.20
Forward P/E Ratio-4.13
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.39 per share
Price / Book3.17
Profitability
EPS (Most Recent Fiscal Year)($3.35)
Net Income$-64,800,000.00
Net MarginsN/A
Return on Equity-50.09%
Return on Assets-46.83%
Miscellaneous
Employees43
Outstanding Shares24,620,000
Market Cap$260.52
Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions
What is Ovid Therapeutics' stock symbol?
Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."
How were Ovid Therapeutics' earnings last quarter?
Ovid Therapeutics Inc (NASDAQ:OVID) posted its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.06. View Ovid Therapeutics' Earnings History.
When is Ovid Therapeutics' next earnings date?
What price target have analysts set for OVID?
3 Wall Street analysts have issued 12-month price targets for Ovid Therapeutics' shares. Their predictions range from $20.00 to $27.00. On average, they expect Ovid Therapeutics' stock price to reach $23.50 in the next year. This suggests a possible upside of 119.0% from the stock's current price. View Analyst Ratings for Ovid Therapeutics.
What is the consensus analysts' recommendation for Ovid Therapeutics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Ovid Therapeutics' key competitors?
Some companies that are related to Ovid Therapeutics include Apellis Pharmaceuticals (APLS), Flexion Therapeutics (FLXN), OptiNose (OPTN), Dynavax Technologies (DVAX), Omeros (OMER), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), ANI Pharmaceuticals Inc Common Stock (ANIP), AC Immune (ACIU) and Amarin (AMRN).
Who are Ovid Therapeutics' key executives?
Ovid Therapeutics' management team includes the folowing people:
- Dr. Jeremy Max Levin, Chairman & CEO (Age 65)
- Dr. Matthew J. During, Founder, Pres, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 61)
- Dr. Yaron Werber, Chief Bus. Officer, CFO & Treasurer (Age 46)
- Ms. Lora Pike, Sr. Director of Investor Relations & PR
- Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Secretray (Age 50)
When did Ovid Therapeutics IPO?
(OVID) raised $80 million in an initial public offering on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.
Has Ovid Therapeutics been receiving favorable news coverage?
News headlines about OVID stock have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ovid Therapeutics earned a coverage optimism score of 0.08 on Accern's scale. They also gave news articles about the company an impact score of 44.95 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Ovid Therapeutics?
Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ovid Therapeutics' stock price today?
One share of OVID stock can currently be purchased for approximately $10.73.
How big of a company is Ovid Therapeutics?
Ovid Therapeutics has a market capitalization of $260.52 million. The company earns $-64,800,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Ovid Therapeutics employs 43 workers across the globe.
How can I contact Ovid Therapeutics?
Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]
MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
